Innoviva Specialty Therapeutics, Inc.

Innoviva Specialty Therapeutics is a subsidiary of Innoviva that develops and delivers therapies for patients in critical care and infectious disease. It markets specialty medicines, including GIAPREZA for septic or distributive shock, XERAVA for complicated intra-abdominal infections, and antibiotics targeting serious bacterial infections. Built by integrating Entasis Therapeutics and La Jolla Pharmaceutical, the company focuses on differentiated treatments for urgent, high-unmet-need conditions, including infections involving antimicrobial resistance.